Jul 9, 2026 04:01PM
Jul 1, 2026 04:05PM
Jul 1, 2026 04:05PM
Jun 15, 2026 04:11PM
Jun 15, 2026 04:10PM
Jun 15, 2026 04:06PM
Jun 15, 2026 04:05PM Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Jun 15, 2026 08:36AM
Jun 15, 2026 08:35AM
Jun 15, 2026 08:30AM
Jun 15, 2026 08:30AM
Jun 8, 2026 04:05PM
Jun 8, 2026 04:05PM
Jun 8, 2026 08:31AM Neurocrine presents INGREZZA data for tardive dyskinesia patients
Jun 8, 2026 08:30AM
Jun 3, 2026 08:31AM
Jun 3, 2026 08:30AM
May 26, 2026 04:01PM
May 21, 2026 04:37PM
May 18, 2026 04:06PM
May 18, 2026 04:05PM Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
May 18, 2026 08:47AM
May 18, 2026 08:46AM
May 6, 2026 08:32AM
May 6, 2026 08:30AM
May 5, 2026 04:01PM
May 5, 2026 09:00AM
May 4, 2026 08:30AM Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
May 4, 2026 07:30AM
May 4, 2026 07:30AM
May 1, 2026 04:06PM
May 1, 2026 04:05PM
Apr 29, 2026 04:07PM
Apr 29, 2026 04:05PM
Apr 22, 2026 04:05PM Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients
Apr 22, 2026 04:05PM
Apr 14, 2026 04:01PM
Apr 14, 2026 08:32AM
Apr 14, 2026 08:30AM
Apr 8, 2026 07:13AM
Apr 6, 2026 01:59PM
Apr 6, 2026 07:01AM Neurocrine to acquire Soleno Therapeutics for $2.9 billion in cash deal
Apr 6, 2026 07:00AM
Mar 26, 2026 08:33AM
Mar 26, 2026 08:30AM
Mar 17, 2026 04:09PM
Mar 17, 2026 04:05PM
Mar 10, 2026 04:01PM
Feb 24, 2026 04:01PM Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Feb 11, 2026 04:01PM

325,297 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All